← Back to patent-cliff list
Apecotrep
Tier C — Watch / tradeApecotrep
Boehringer Ingelheim
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TRPC6
Indications (approved)：局灶性节段性肾小球硬化症, 蛋白尿, Nephropathy, Kidney disease, Chronic renal impairment, COVID-19
Regional status
US
Phase III
2026-02-16
EU
Phase III
2026-02-16
China
Phase III
2026-02-16
Japan
Phase III
2026-02-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Apecotrep?
Approved indications include: 局灶性节段性肾小球硬化症, 蛋白尿, Nephropathy, Kidney disease, Chronic renal impairment, COVID-19.
When does the Apecotrep patent expire?
No public expiry year is available for Apecotrep yet; this page updates once verified.
How do I get a quote for Apecotrep intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29